These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28661555)

  • 1. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
    Weiss C; Figueras E; Borbely AN; Sewald N
    J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent approaches for the synthesis of modified cryptophycins.
    Weiss C; Sammet B; Sewald N
    Nat Prod Rep; 2013 Jul; 30(7):924-40. PubMed ID: 23732943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
    Shih C; Teicher BA
    Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
    Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
    Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a new class of cryptophycins based tubulin inhibitors.
    Kumar A; Kumar M; Sharma S; Guru SK; Bhushan S; Shah BA
    Eur J Med Chem; 2015 Mar; 93():55-63. PubMed ID: 25647428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cryptophycins as potent payloads for antibody drug conjugates.
    Verma VA; Pillow TH; DePalatis L; Li G; Phillips GL; Polson AG; Raab HE; Spencer S; Zheng B
    Bioorg Med Chem Lett; 2015 Feb; 25(4):864-8. PubMed ID: 25613677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
    Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
    Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
    Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimitotic peptides and depsipeptides.
    Hamel E; Covell DG
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):19-53. PubMed ID: 12678750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cryptophycins: their synthesis and anticancer activity.
    Eggen M; Georg GI
    Med Res Rev; 2002 Mar; 22(2):85-101. PubMed ID: 11857635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
    Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
    Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
    Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
    Mooberry SL; Leal RM; Tinley TL; Luesch H; Moore RE; Corbett TH
    Int J Cancer; 2003 Apr; 104(4):512-21. PubMed ID: 12584751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
    Al-Awar RS; Corbett TH; Ray JE; Polin L; Kennedy JH; Wagner MM; Williams DC
    Mol Cancer Ther; 2004 Sep; 3(9):1061-7. PubMed ID: 15367700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
    Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis.
    Nahrwold M; Weiß C; Bogner T; Mertink F; Conradi J; Sammet B; Palmisano R; Royo Gracia S; Preuße T; Sewald N
    J Med Chem; 2013 Mar; 56(5):1853-64. PubMed ID: 23387527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
    Mitra A; Sept D
    Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient synthesis of cryptophycin-52 and novel para-alkoxymethyl unit A analogues.
    Eissler S; Bogner T; Nahrwold M; Sewald N
    Chemistry; 2009 Oct; 15(42):11273-87. PubMed ID: 19760734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
    Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.